Ophthalmology Times

FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Healio

FDA fast tracks CTx001 for geographic atrophy

The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Nature

Inhibitors of C5 complement enhance vaccinia virus oncolysis

Genetically engineered tumor-selective vaccinia virus (VV) has been demonstrated to be a highly effective oncolytic agent, but immune clearance may limit its therapeutic potential. As previously ...
Medindia

Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
JSTOR Daily

Actions of Complement on Junin Virus

Reviews of Infectious Diseases, Vol. 11, Supplement 4. Hemostatic Impairment Associated with Hemorrhagic Fever Viruses (May - Jun., 1989), pp. S771-S776 (6 pages) Fresh sera from normal rhesus monkeys ...
Nature

Combatting complement

Work published in the Proceedings of the National Academy of Sciences by Rosengard and colleagues helps to explain one way in which variola virus, the causative agent of smallpox, successfully evades ...
JSTOR Daily

A Study of Foot-and-Mouth Disease Virus Strains by Complement Fixation: I. A Model for the Fixation of Complement by Antigen/Antibody Mixtures

An examination was made of the relations between antigen, antibody and fixation of complement with foot-and-mouth disease virus (FMDV). It was found that complement fixation in this system follows the ...